Angemeldet als:
filler@godaddy.com
Kuros ends transformational year
December 17, 2018: Kuros ends transformational year with first MagnetOs sales, lead clinical program on track, and successful capital raise.
Kuros successfully raised CHF 16.1 million from existing and new investors. (read more)
Octavian was acting as Joint Placement Agent
Poenina successfully completes its CHF 35 million rights offering
November 2, 2018: Poenina Holding AG (PNHO.SW) today announced the successful completion of its CHF 35 million rights offering to fund the acquisition of the Inretis Group.
Link to Poenina's press release (in German language only)
Octavian was acting as Selling Agent
Octavian Top 5 for Q4 2018
October 1, 2018: Today we publish our 'TOP 5' list for Q4 2018. Subscribers can access the full report on the RSRCHX platform via the link below and on our Bloomberg homepage {OCTV <GO>}
Link to 'TOP 5' Q4 2018 report on RSRCHX
If you cannot access the report please do not hesitate to contact us at sales@octavian.ch
Idorsia successfully completes the offering of new shares and convertible bonds
July 11, 2018: Idorsia Ltd (IDIA.SW) today announced that it has successfully placed 11,912,000 new shares, corresponding to approximately 10% of Idorsia's currently issued share capital, by way of an accelerated bookbuilding. Additionally, Idorsia successfully placed CHF 200 million of senior unsecured convertible bonds due 2024.
Link to Idorsia's press release
Octavian was acting as Selling Agent
Octavian 'TOP 5' for Q3 2018
July 2, 2018: Today we publish our 'TOP 5' List for Q3 2018. The full report can be accessed through the RSRCHX platform via the link below and on our Bloomberg homepage {OCTV <GO>}
If you cannot access the report please do not hesitate to contact us at sales@octavian.ch
Polyphor prices its IPO at CHF 38 per share and lists on SIX Swiss Exchange
May 15, 2018: Polyphor Ltd ("Polyphor" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative antibiotics and other specialty pharma products for severe or life-threatening diseases, today set the offer price for its shares in the initial public offering (“IPO”) at CHF 38 per share, at the upper end of the offer price range.
Octavian was acting as Selling Agent
Octavian 'TOP 5' for Q2 2018
April 2, 2018: Today we publish our 'TOP 5' List for Q2 2018. The full report can be accessed through the RSRCHX platform via the link below and on our Bloomberg homepage {OCTV <GO>}
If you cannot access the report please do not hesitate to contact us at sales@octavian.ch
Addex Sucessfully Raises CHF40 million in Capital Increase
March 29, 2018: Addex Therapeutics (SIX: ADXN), the leading developer of oral allosteric modulators for neurological disorders, announced today that the company has successfully completed its capital increase, raising CHF40 million.
Octavian was acting as Placement Agent.
OCTAVIAN SEMINAR 2018
January 20, 2018: A big thank you to all of the companies and investors that attended the OCTAVIAN SEMINAR 2018 in Zurich and Flims.
Please save the date for the next one:
OCTAVIAN SEMINAR 2019
January 17-19, 2019
Now off to the slopes...
Octavian 'TOP 5' for Q1 2018
January 2, 2018: Our 'TOP 5' for Q1 2018 can now be accessed through the RSRCHX platform via the link below and on our Bloomberg homepage {OCTV <GO>}
If you cannot access the report please do not hesitate to contact us at sales@octavian.ch
Octavian on stage at the inaugural Swiss IPO Day 2017
November 28, 2017: Octavian presents on stage in front of 15 grownup Swiss startup companies at the inaugural Swiss IPO Day 2017. Many thanks to the organizers at Swiss Startup Invest for this unconventional and refreshing event.
ADC Therapeutics Announces Closing of $200 Million Private Financing
October 23, 2017: The Octavian team congratulates ADC Therapeutics (ADCT), an oncology drug development company that specializes in the development of proprietary PBD-based Antibody Drug Conjugates targeting major cancers, to the successful raise of $200 million through a private placement. Octavian supported ADCT in this private placement with targeted access to its investor client base resulting in the addition of new quality investors to ADCT’s shareholder registry.
Octavian 'TOP 5' for Q4 2017
October 2, 2017: We are delighted to bring you the second installment of our quarterly 'TOP 5' picks as Team Octavian. The full report can be a accessed on the following link:
Octavian 'TOP 5' for Q3 2017
July 3, 2017: We are delighted to present you with our first 'TOP 5' List for Q3 2017 under the Octavian name. The full report can be accessed through the RSRCHX platform via the link below.